IPO roundup: MAP Pharma’s mixed reception, other recent filings
MAP Pharmaceuticals, the Mountain View, Calif., specialty pharma, had a mixed reception to its IPO Friday. The company priced its shares at $12, below its anticipated range of $14 to $16, raising up to $69 million — substantially less than the $92 million it might have pulled in. Investors, however, reacted positively and pushed up the shares 11 percent to $13.35.
MAP reformulates existing drugs in order to deliver them via inhalers. Its leading product is… Continue Reading